Assuntos
Adalimumab , Síndrome de Behçet , Hidradenite , Humanos , Adalimumab/uso terapêutico , Adalimumab/efeitos adversos , Síndrome de Behçet/tratamento farmacológico , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/complicações , Hidradenite/induzido quimicamente , Hidradenite/tratamento farmacológico , Hidradenite/patologia , Masculino , Anti-Inflamatórios/uso terapêutico , Adulto , Feminino , Neutrófilos/patologiaRESUMO
Neuropathic ulcers in leprosy represent a therapeutic challenge for clinicians. Chronic ulcers affect patient health, emotional state and quality of life, causing considerable morbidity and mortality in addition to contributing to significant health care costs. The pathogenesis is mainly related to the abnormally increased pressure in areas such as the sole of the foot, secondary to lack of sensation and deformities induced by peripheral sensory-motor neuropathy. Conventional treatment of these wounds can be slow due to their chronic inflammatory state and the senescence of local reparative cells. Platelet-rich plasma (PRP) may restore the healing process, leading to a reparative phase. We present two patients with four neuropathic leprosy ulcers that have responded satisfactory to PRP treatment. PRP therapy has been growing as a viable treatment alternative for chronic ulcers. However, stronger scientific evidence is required to support its potential benefit for use in chronic wounds.
Assuntos
Doença Crônica/tratamento farmacológico , Úlcera do Pé/tratamento farmacológico , Hanseníase/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Plasma Rico em Plaquetas , Cicatrização/fisiologia , Idoso , Neuropatias Diabéticas , Feminino , Úlcera do Pé/diagnóstico , Humanos , Injeções Intralesionais , Hanseníase/diagnóstico , Masculino , Doenças do Sistema Nervoso Periférico/diagnóstico , Resultado do TratamentoAssuntos
Antagonistas Adrenérgicos beta/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Dermatoses Faciais/induzido quimicamente , Levobunolol/imunologia , Timolol/efeitos adversos , Timolol/imunologia , Corticosteroides/uso terapêutico , Antagonistas Adrenérgicos beta/imunologia , Reações Cruzadas , Dermatite Alérgica de Contato/tratamento farmacológico , Pálpebras , Dermatoses Faciais/tratamento farmacológico , Glaucoma/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Soluções OftálmicasRESUMO
Both of these young patients presented with rashes that had spread from their abdomen to their arms and legs--but only on one side.
Assuntos
Exantema/diagnóstico , Exantema/tratamento farmacológico , Antagonistas dos Receptores Histamínicos/administração & dosagem , Prurido/diagnóstico , Prurido/tratamento farmacológico , Administração Oral , Adolescente , Pré-Escolar , Feminino , Humanos , Masculino , Gravidez , Doenças Raras/diagnóstico , Doenças Raras/tratamento farmacológico , Resultado do TratamentoRESUMO
Nuclear 3'-end-polyadenylation is essential for the transport, stability and translation of virtually all eukaryotic mRNAs. Poly(A) tail extension can also occur in the cytoplasm, but the transcripts involved are incompletely understood, particularly in cancer. Here we identify a lineage-specific requirement of the cytoplasmic polyadenylation binding protein 4 (CPEB4) in malignant melanoma. CPEB4 is upregulated early in melanoma progression, as defined by computational and histological analyses. Melanoma cells are distinct from other tumour cell types in their dependency on CPEB4, not only to prevent mitotic aberrations, but to progress through G1/S cell cycle checkpoints. RNA immunoprecipitation, sequencing of bound transcripts and poly(A) length tests link the melanoma-specific functions of CPEB4 to signalling hubs specifically enriched in this disease. Essential in these CPEB4-controlled networks are the melanoma drivers MITF and RAB7A, a feature validated in clinical biopsies. These results provide new mechanistic links between cytoplasmic polyadenylation and lineage specification in melanoma.